Metabolic syndrome among hypertensive patients at University of Gondar Hospital, North West Ethiopia: a cross sectional study

BMC Cardiovascular Disorders

Nebiyu Mesfin²  Zelalem Addis¹  Molla Abebe³  Belaynesh Tachebele⁴ 

[1] Department of Medical Microbiology, University of Gondar, School of Biomedical and Laboratory Sciences, Gondar, Ethiopia;Department of Internal Medicine, University of Gondar, School of Medicine, Gondar, Ethiopia;Department of Clinical Chemistry, University of Gondar, School of Biomedical and Laboratory Sciences, Gondar, Ethiopia;University of Gondar Hospital, Hospital Laboratory, Gondar, Ethiopia

关键词: Insulin resistance;    Dyslipidemia;    Cardiovascular risk;    Metabolic syndrome;    Hypertension;   

Others  :  1088418
DOI  :  10.1186/1471-2261-14-177

 received in 2014-08-03, accepted in 2014-12-02,  发布年份 2014

【 摘 要 】

Background

Data is sparse concerning the magnitude of metabolic syndrome (MetS) in developing countries like Ethiopia whose major health problem had long been under-nutrition and infectious diseases rather than non-communicable diseases (NCDs) including hypertension, obesity and MetS. However, it is obvious that the NCDs are recently taking over and becoming the major health care concerns in the developing countries. This pattern could be partly explained by the nation’s sustained economical growth in the last few decades in addition to the increasing globalization related adoption of western lifestyle. The aim of this study was to assess the prevalence of metabolic syndrome and associated factors among hypertensive patients in North West Ethiopia.

Method

A cross sectional study was conducted on 300 hypertensive individuals who get follow-up care at University of Gondar Hospital after diagnosed as hypertensive. The WHO STEP-wise approach to surveillance of NCD was used. Fasting blood glucose level, triglyceride and high density lipoprotein cholesterol were determined using standardized laboratory procedures.

Result

The prevalence of metabolic syndrome was 40.7% and 39.3% according to the modified NCEP-ATP III and IDF criteria respectively. Low HDL-c was found to be the most frequently encountered (81.3%) component of MetS other than the hypertension. Being female was significantly associated with MetS (AOR = 4.34; 95% CI: 2.09, 8.99) using IDF and (AOR = 3.30; 95% CI: 1.66, 6.58) using NCEP-ATP III criteria. Abnormal BMI which included both high and low BMI was found to have significant association with MetS (AOR = 3.10; 95% CI: 1.73, 5.58) using IDF and (AOR = 1.84; 95% CI: 1.05, 3.22) as diagnosed using the NCEP-ATP III criteria.

Conclusion

We recommend a comprehensive medical care approach to hypertensive patients to adequately assess and address the additional components of MetS which are known to potentiate the risks of cardiovascular diseases among hypertensive patients.

【 授权许可】

   
2014 Tachebele et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH: The metabolic syndrome. Endocr Rev 2008, 29:777-822.
• [2]Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
• [3]World Health Organization (WHO): Non-Communicable Diseases Country Profile. 2011.
• [4]International diabetes federation (IDF): The IDF consensus worldwide definition of the metabolic syndrome. 2006. http://www.idf.org/webdata/docs/MetS_def_update2006.pdf webcite
• [5]Osuji CU, Omejua EG: Prevalence and characteristics of the metabolic syndrome among newly diagnosed hypertensive patients. Indian J Endocrinol Metab 2012, 16:104-109.
• [6]Marchi-Alves LM, Rigotti AR, Nogueira MS, Cesarino CB, de Godoy S: Metabolic syndrome components in arterial hypertension. S Rev Esc Enferm USP 2012, 46:1348-1353.
• [7]Hsu CN, Chen YC, Wang TD: Prevalence and characteristics of the metabolic syndrome in Chinese hypertensive patients: a hospital-based observation. Acta Cardiol Sin 2005, 21:89-97.
• [8]Hilgers KF, Mann JF: The choice of antihypertensive therapy in patients with the metabolic syndrome–time to change recommendations? Nephrol Dial Transplant 2008, 23:3389-3391.
• [9]Sorkhou EI, Al-Qallaf B, Al-Namash HA, Ben-Nakhi A, Al-Batish MM, Habiba SA: Prevalence of metabolic syndrome among hypertensive patients attending a primary care clinic in Kuwait. Med Princ Pract 2004, 13:39-42.
• [10]Pierdomenico SD, Lapenna D, Di Tommaso R, Di Carlo S, Caldarella MP, Neri M, Mezzetti A, Cuccurullo F: Prognostic relevance of metabolic syndrome in hypertensive patients at low-to-medium risk. Am J Hypertens 2007, 20:1291-1296.
• [11]Tran A, Gelaye B, Girma B, Lemma S, Berhane Y, Bekele T, Khali A, Williams MA: Prevalence of metabolic syndrome among working adults in Ethiopia. Int J Hypertens 2011. doi:10.4061/2011/193719
• [12]Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M, Deribe K: Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med J 2012, 13:43-60.
• [13]Su CH, Fang CY, Chen JS, Po HL, Chou LP, Chiang CY, Ueng KC: Prevalence of metabolic syndrome and its relationship with cardiovascular disease among hypertensive patients 55-80 years of age. Acta Cardiol Sin 2011, 27:229-237.
• [14]World Health Organization (WHO): Chronic diseases and health promotion: Stepwise approach to surveillance (STEPS). 2010. http://www.who.int/chp/steps/instrument/STEPS_Instrument_V3.1.pdf webcite
• [15]Lemogoum D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere B, Blackett KN, Lenfant C, Kabangu JR, Block P, Belhocine M, Degaute JP: Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2003, 21:1993-2000.
• [16]Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diab Care 2004, 27:2676-2681.
• [17]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [18]Ogbu ISI, Ugwuja EI: Metabolic syndrome in hypertensive nigerians: risk factor analysis. IOSR J Pharm Biol Sci 2012, 4:28-32.
• [19]Lioudaki E, Vrentzos GE, Mavrogeni H, Zeniodi MH, Ganotakis ES, Mikhailidis DP, Papadakis JA: Prevalence of metabolic syndrome according to different definitions in a hypertensive population. Angiology 2012, 63:39-47.
• [20]Yasein N, Ahmad M, Matrook F, Nasir L, Froelicher ES: Metabolic syndrome in patients with hypertension attending a family practice clinic in Jordan. East Mediterr Health J 2010, 16:375-380.
• [21]Shahbazian H, Latifi SM, Jalali MT, Shahbazian H, Amani R, Nikhoo A, Aleali AM: Metabolic syndrome and its correlated factors in an urban population in South West of Iran. J Diab Metab Disord 2013, 12:11. BioMed Central Full Text
• [22]Delisle H, Ntandou G, Després JP: At-risk serum cholesterol profile at both ends of the nutrition spectrum in West African adults? The Benin Study. Nutrients 2013, 5(4):1366-1383.